Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-21	JP¥68.00	+1.49%	1,109,400
26-08-20	JP¥67.00	+1.52%	751,200
26-08-19	JP¥66.00	-4.35%	1,939,900
26-08-18	JP¥69.00	-1.43%	2,183,700
26-08-17	JP¥70.00	+4.48%	3,000,900

Delayed Quote Japan Exchange

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange 02:30:00 2026-08-21 EDT			5-day change	1st Jan Change
68.00 ^JPY	+1.49%		+1.49%	+61.90%

08-14	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-14	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	11.03B 9.44B 8.84B 8.09B 15.18B 1,055B 15.38B 104B 40.72B 530B 41.4B 40.5B 1,753B	P/E 2024	-2.24x	P/E 2025	-3.97x
Enterprise Value	9.13B 7.82B 7.32B 6.7B 12.57B 873B 12.74B 86.44B 33.71B 439B 34.28B 33.53B 1,451B	EV / Sales 2024	57.4x	EV / Sales 2025	140x
Free-Float	59.16%	Yield 2024 *	-	Yield 2025	-

08-14	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-14	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-04	Kubota Vision signs supply & licensing agreement with Laboratoires Kôl	RE
02-12	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-21	Kubota Pharmaceutical Holdings Co., Ltd. announced that it has received ¥315.0045 million in funding from Kubota Asset Management Co., Ltd.	CI
11-16	Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive KRW 315.0045 million in funding	CI
24-09-04	Kubota Pharmaceutical Holdings Co., Ltd. announced that it has received ¥1.12 million in funding from Barclays PLC	CI
24-08-19	Kubota Pharmaceutical Holdings Co., Ltd. announced that it expects to receive ¥1.12 million in funding from Barclays PLC	CI
24-03-21	Kubota Pharmaceutical Adjusts 2023 Financial Results Following Reevaluation	MT
24-03-21	Kubota Pharmaceutical Holdings Co., Ltd. Restates Consolidated and Non-Consolidated Financial Results for the Fiscal Year Ended December 31, 2023	CI
24-02-14	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-14	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
23-08-10	Kubota Pharmaceutical Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

23-02-24	Kubota Pharmaceutical Group Launches Its Unique Kubota Glass Technology Aiming to Revolutionize Myopia Management	NE
21-08-12	Kubota Pharmaceutical : Summary of Financial Results for the second quarter 2021	PU
21-08-12	Kubota Pharmaceutical : Consolidated Financial Results for the Six Months Ended June 30, 2021(under IFRS)	PU
21-05-13	Kubota Pharmaceutical : Consolidated Financial Results for the Three Months Ended March 31, 2021(under IFRS)	PU

Kubota Pharmaceutical Holdings Co., Ltd. Stock

Stocks

4596

JP3266500002

Pharmaceuticals

Valuation: Kubota Pharmaceutical Holdings Co., Ltd.

Chart: Kubota Pharmaceutical Holdings Co., Ltd.

Latest news : Kubota Pharmaceutical Holdings Co., Ltd.

Press Releases: Kubota Pharmaceutical Holdings Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Kubota Pharmaceutical Holdings Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	+1.49%
1 week	+1.49%
Current month	+15.25%
1 month	+3.03%
3 months	+1.49%
6 months	-62.84%
Current year	+61.90%

Manager	Title	Age	Since
Ryo Kubota CEO	Chief Executive Officer	59	2015-12-10
Kazunori Watanabe DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Ryo Kubota CHM	Chairman	59	2015-12-10
Yuki Nakagawa BRD	Director/Board Member	43	2025-04-17
Masa Fujiwara BRD	Director/Board Member	56	2025-04-17

	2024	2025
Net sales	27M 23.13M 21.64M 19.81M 37.18M 2.58B 37.67M 256M 99.71M 1.3B 101M 99.18M 4.29B	21M 17.99M 16.83M 15.41M 28.92M 2.01B 29.3M 199M 77.55M 1.01B 78.85M 77.14M 3.34B
Net income	-1.33B -1.14B -1.07B -977M -1.83B -127B -1.86B -12.61B -4.92B -64.02B -5B -4.89B -212B	-676M -579M -542M -496M -931M -64.68B -943M -6.4B -2.5B -32.49B -2.54B -2.48B -107B
Net Debt	-1.44B -1.24B -1.16B -1.06B -1.99B -138B -2.01B -13.67B -5.33B -69.4B -5.42B -5.3B -230B	-1.9B -1.62B -1.52B -1.39B -2.61B -182B -2.65B -17.96B -7.01B -91.18B -7.12B -6.97B -302B

1 week	65	72
1 month	55	72
Current year	42	350
1 year	41	350
3 years	38	350
5 years	38	350
10 years	38	1,425

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.	+1.49%	+1.49%	+30.77%	-29.90%	69.36M
ELI LILLY AND COMPANY	+0.88%	+6.38%	+76.86%	+128.23%	1,119B
JOHNSON & JOHNSON	+1.07%	+3.80%	+51.03%	+61.48%	651B
ABBVIE INC.	+1.20%	+6.21%	+26.47%	+76.45%	468B
ROCHE HOLDING AG	+1.02%	+5.77%	+43.09%	+47.70%	374B
NOVARTIS AG	+0.85%	+4.07%	+23.88%	+41.58%	302B
ASTRAZENECA PLC	+1.26%	+6.81%	+1.59%	+14.67%	259B
AMGEN INC.	+1.88%	+5.81%	+48.54%	+68.52%	238B
NOVO NORDISK A/S	+1.59%	+2.09%	-15.52%	-52.29%	208B
GILEAD SCIENCES, INC.	+1.87%	+5.61%	+25.81%	+92.42%	181B
Average	+1.31%	+4.63%	+31.25%	+44.89%	379.99B
Weighted average by Cap.	+1.14%	+5.09%	+44.31%	+72.55%